Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 5/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23903252 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL23883393 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL23903260 | 0.97 | CYP3A4 (0.50) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL25721153 | 0.97 | CYP3A4 (0.50) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL23903254 | 0.97 | CYP3A4 (0.52) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL23903259 | 0.97 | CYP3A4 (0.50) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL23902958 | 0.97 | CYP3A4 (0.50) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL23903407 | 0.96 | CYP3A4 (0.47) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL26158891 | 0.95 | CYP3A4 (0.44) | CYP3A4CYP2D6THPOMTORMEN1 | |
| SCHEMBL26158896 | 0.95 | CYP3A4 (0.44) | CYP3A4CYP2D6THPOMTORMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734960-A1 | STEROL ANALOGS IN LIPID NANOPARTICLE FORMULATIONS | Sanofi Pasteur Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025003760-A1 | STEROL ANALOGS IN LIPID NANOPARTICLE FORMULATIONS | SANOFI (FR) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024126809-A1 | MRNA ENCODING INFLUENZA VIRUS-LIKE PARTICLE | SANOFI (FR) | 2024-06-20 | — | — | WO | disclosed |
| US-20230355524-A1 | METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES | TRANSLATE BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355524-A1 | METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES | TRANSLATE BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230190954-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | TRANSLATE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230181619-A1 | IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPY | TRANSLATE BIO, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230181619-A1 | IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPY | TRANSLATE BIO, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023086893-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | TRANSLATE BIO, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230150921-A1 | PHENOLIC ACID LIPID BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023278754-A1 | COMPOSITIONS FOR DELIVERY OF MRNA | TRANSLATE BIO, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022115547-A1 | STABLE LIQUID LIPID NANOPARTICLE FORMULATIONS | TRANSLATE BIO, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220160633-A1 | COMPOSITIONS FOR DELIVERY OF CODON-OPTIMIZED MRNA | TRANSLATE BIO, INC. | 2022-05-26 | — | — | US | disclosed |
| WO-2022099194-A1 | IMPROVED COMPOSITIONS FOR DELIVERY OF CODON-OPTIMIZED MRNA | TRANSLATE BIO, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021226463-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | TRANSLATE BIO, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226468-A1 | IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPY | TRANSLATE BIO, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021202694-A1 | PHENOLIC ACID LIPID BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150921-A1 | PHENOLIC ACID LIPID BASED CATIONIC LIPIDS | SLC27A1, SREBF1, SREBF2 | CYP3A4 4032/4885CYP2D6 2662/4885THPO 1807/4885 |
| US-20220160633-A1 | COMPOSITIONS FOR DELIVERY OF CODON-OPTIMIZED MRNA | RNGTT, RNMT, UPF1 | CYP3A4 4159/4885CYP2D6 2554/4885THPO 1679/4885 |
| US-20230355524-A1 | METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES | IL23R, IL5, IL33 | CYP3A4 2414/4885CYP2D6 1026/4885THPO 2356/4885 |
| US-20230190954-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | DNAH12, DYNC1I2, DYNC1H1 | CYP3A4 4884/4885CYP2D6 4861/4885THPO 4332/4885 |
| US-20230181619-A1 | IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPY | CFTR, UPF1, RNGTT | CYP3A4 4482/4885CYP2D6 4462/4885THPO 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.